161 related articles for article (PubMed ID: 31777737)
1. Prevalence and oncologic outcomes of
Seo JH; Jeong SY; Kim MS; Kang JH; Paik ES; Lee YY; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
Obstet Gynecol Sci; 2019 Nov; 62(6):411-419. PubMed ID: 31777737
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Clinical Outcomes of
Eoh KJ; Park HS; Park JS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
Cancer Res Treat; 2017 Apr; 49(2):408-415. PubMed ID: 27488874
[TBL] [Abstract][Full Text] [Related]
3. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
[TBL] [Abstract][Full Text] [Related]
4. Germline and Somatic
You Y; Li L; Lu J; Wu H; Wang J; Gao J; Wu M; Liang Z
Front Oncol; 2020; 10():295. PubMed ID: 32211327
[No Abstract] [Full Text] [Related]
5. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.
Yang D; Khan S; Sun Y; Hess K; Shmulevich I; Sood AK; Zhang W
JAMA; 2011 Oct; 306(14):1557-65. PubMed ID: 21990299
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and Spectrum of
Foglietta J; Ludovini V; Bianconi F; Pistola L; Reda MS; Al-Refaie A; Tofanetti FR; Mosconi A; Minenza E; Anastasi P; Molica C; Stracci F; Roila F
Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32806537
[TBL] [Abstract][Full Text] [Related]
7. Association Between Germline
Luo Y; Pan R; Rao H; Chen X; Yang H
Int J Gen Med; 2024; 17():75-84. PubMed ID: 38226182
[TBL] [Abstract][Full Text] [Related]
8. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
9. Germline
Mehta A; Vasudevan S; Sharma SK; Kumar D; Panigrahi M; Suryavanshi M; Gupta G
Cancer Manag Res; 2018; 10():6505-6516. PubMed ID: 30555256
[TBL] [Abstract][Full Text] [Related]
10. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
[TBL] [Abstract][Full Text] [Related]
11. Reclassification of
Ha HI; Ryu JS; Shim H; Kong SY; Lim MC
J Gynecol Oncol; 2020 Nov; 31(6):e83. PubMed ID: 33078592
[TBL] [Abstract][Full Text] [Related]
12. Landscape of germline
Ferreyra Y; Rosas G; Cock-Rada AM; Araujo J; Bravo L; Doimi F; Casas J; Clavo MLÁ; Pinto JA; Belmar-López C
Front Oncol; 2023; 13():1227864. PubMed ID: 37664050
[TBL] [Abstract][Full Text] [Related]
13. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
Birkbak NJ; Kochupurakkal B; Izarzugaza JM; Eklund AC; Li Y; Liu J; Szallasi Z; Matulonis UA; Richardson AL; Iglehart JD; Wang ZC
PLoS One; 2013; 8(11):e80023. PubMed ID: 24265793
[TBL] [Abstract][Full Text] [Related]
14. Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer.
Hyman DM; Zhou Q; Iasonos A; Grisham RN; Arnold AG; Phillips MF; Bhatia J; Levine DA; Aghajanian C; Offit K; Barakat RR; Spriggs DR; Kauff ND
Cancer; 2012 Aug; 118(15):3703-9. PubMed ID: 22139894
[TBL] [Abstract][Full Text] [Related]
15. Clinical Decision-Making in Patients with Variant of Uncertain Significance in BRCA1 or BRCA2 Genes.
Welsh JL; Hoskin TL; Day CN; Thomas AS; Cogswell JA; Couch FJ; Boughey JC
Ann Surg Oncol; 2017 Oct; 24(10):3067-3072. PubMed ID: 28766224
[TBL] [Abstract][Full Text] [Related]
16. Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.
Spearman AD; Sweet K; Zhou XP; McLennan J; Couch FJ; Toland AE
J Clin Oncol; 2008 Nov; 26(33):5393-400. PubMed ID: 18824701
[TBL] [Abstract][Full Text] [Related]
17. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
18. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
[TBL] [Abstract][Full Text] [Related]
19.
Manchana T; Tantbirojn P; Pohthipornthawat N
Gynecol Oncol Rep; 2020 Aug; 33():100582. PubMed ID: 32529018
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the Prognostic Value of Two Common Variants of BRCA1 and BRCA2 Genes in Ovarian Cancer Patients Treated with Cisplatin and Paclitaxel: A Gynecologic Oncology Group Study.
Tian CQ; Darcy KM; Krivak TC; Deloia JA; Armstrong D; Davis W; Zhao H; Moysich K; Ambrosone CB
Front Oncol; 2013; 3():206. PubMed ID: 23964347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]